MedTrace Logo

A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

NCT03092739 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 184

Last updated 2019-07-23

No results posted yet for this study

Summary

The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with any stage of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Small Cell

Interventions

DIAGNOSTIC_TEST

PD-L1 Immunocytochemistry (ICC)

PD-L1 expression in the cytological specimens will be assessed using different antibodies.

DIAGNOSTIC_TEST

PD-L1 Immunohistochemistry (IHC)

PD-L1 expression in the histological specimens will be assessed using different antibodies.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-03
Primary Completion
2018-01-08
Completion
2018-06-06

Countries

  • Czechia
  • Germany
  • Poland
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03092739 on ClinicalTrials.gov